With cell and gene therapies growing more and more ... Milestone payments can also serve as an element of outcomes-based agreements. Another model that could help control the cost burden of ...

Investigators from New York State Office for People with Developmental Disabilities (OPWDD) and affiliated organizations have reported the discovery and preclinical characterization of a gene therapy ...

CMS has negotiated outcomes-based agreements for sickle cell gene therapies with the two companies on behalf of participating state Medicaid programs.